Blood Clotting Accelerant Market

Blood clotting accelerants are used to enhance the process of blood clotting within a shorter period of time than it would require normally. Blood clotting is a complex mechanism which involves various factors and normal coagulation functioning in a patient is screened by tests prior to surgeries. The use of blood clotting accelerant is increasing in clinical spheres as a result of increasing incidence of conditions like hemophilia, anemia, thrombolysis, pulmonary embolism (PE), deep vein thrombosis (DVT), liver diseases, surgical treatments and genetically inherited deficiencies which impede normal coagulation process and can be confirmed via blood clotting accelerants. According to the National Hemophilia Foundation, von Willebrand disease affects up to 1% of US population. Current gene therapy research trials are focused on methods to insert factor VIII genes into hemophilic patients to restore normal coagulation functioning.
Blood Clotting Accelerant Market contains market size and forecasts of Blood Clotting Accelerant in global, including the following market information:
Global Blood Clotting Accelerant Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Blood Clotting Accelerant Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Blood Clotting Accelerant companies in 2021 (%)
The global Blood Clotting Accelerant market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Powder Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Blood Clotting Accelerant include Merck KgaA, Baxter International Inc, CSL Ltd., Inc., Grifols International SA, Kedrion S.P.A., Novo Nordisk A/S, Octapharma AG, PeproTech, Inc. and ACROBiosystems. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Blood Clotting Accelerant manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Blood Clotting Accelerant Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, by Type, 2021 (%)
Powder
Solution
Global Blood Clotting Accelerant Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Diagnostic Laboratories
Research Institutes
Global Blood Clotting Accelerant Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Blood Clotting Accelerant Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Blood Clotting Accelerant revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Blood Clotting Accelerant revenues share in global market, 2021 (%)
Key companies Blood Clotting Accelerant sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Blood Clotting Accelerant sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck KgaA
Baxter International Inc
CSL Ltd., Inc.
Grifols International SA
Kedrion S.P.A.
Novo Nordisk A/S
Octapharma AG
PeproTech, Inc.
ACROBiosystems